Patents Represented by Attorney Lucy J. Incyte Pharmaceuticals, Inc. Billings
-
Patent number: 5876963Abstract: The invention provides a human nucleotide pyrophosphohydrolase (NTPPH-1) and polynucleotides which identify and encode NTPPH-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-1.Type: GrantFiled: August 27, 1997Date of Patent: March 2, 1999Inventors: Peter Mitchell, Nancy Hutchinson, Michael Lawton, Holly Magna, Sue Yocum, Lynn E. Murry
-
Patent number: 5874211Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: GrantFiled: April 13, 1995Date of Patent: February 23, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Susan G. Stuart
-
Patent number: 5874286Abstract: The present invention provides novel human tumor proteins (collectively called TUPRO) and polynucleotides which identify and encode TUPRO. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TUPRO. The invention also provides pharmaceutical compositions containing TUPRO or antagonists to TUPRO, and in the use of these compositions for the treatment of diseases associated with the expression of TUPRO. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TUPRO for the treatment of diseases associated with the expression of TUPRO. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding TUPRO or anti-TUPRO antibodies which specifically bind to TUPRO.Type: GrantFiled: September 17, 1996Date of Patent: February 23, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5871930Abstract: The invention provides a human high affinity immunoglobulin E receptor-like protein (IGERB) and polynucleotides which identify and encode IGERB. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IGERB.Type: GrantFiled: August 21, 1997Date of Patent: February 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 5871970Abstract: The present invention provides a human calcium-binding protein (HCBP) and polynucleotides which identify and encode HCBP. The invention also provides expression vectors and host cells, agonists, antibodies, and antagonists. In addition, the invention provides methods for producing HCBP and for treating or preventing disorders associated with the expression of HCBP.Type: GrantFiled: March 31, 1997Date of Patent: February 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5872234Abstract: The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.Type: GrantFiled: June 27, 1997Date of Patent: February 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler
-
Patent number: 5869639Abstract: The present invention provides two human p24 vesicle trafficking proteins (designated individually as Hp24-1 and Hp24-2 and collectively as Hp24) and polynucleotides which identify and encode Hp24. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Hp24 and a method for producing Hp24. The invention also provides for agonists, antibodies, or antagonists specifically binding Hp24, and their use, in the prevention and treatment of diseases associated with expression of Hp24. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Hp24 for the treatment of diseases associated with the expression of Hp24. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Hp24.Type: GrantFiled: February 14, 1997Date of Patent: February 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Olga Bandman
-
Patent number: 5869637Abstract: The present provides a polynucleotide which identifies and encodes a novel human kallikrein (HKLP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HKLP. The invention also provides for the use of substantially purified HKLP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HKLP. Additionally, the invention provides for the use of antisense molecules to HKLP in pharmaceutical compositions for treatment of diseases associated with the expression of HKLP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HKLP or anti-HKLP antibodies which specifically bind to HKLP.Type: GrantFiled: July 22, 1996Date of Patent: February 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Olga Bandman, Scott Michael Braxton, Surya K. Goli
-
Patent number: 5869291Abstract: The present invention provides three Rab proteins (designated individually as HRABS-1, HRABS-2, and HRABS-3, and collectively as HRABS) and polynucleotides which identify and encode HRABS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRABS and a method for producing HRABS. The invention also provides for use of HRABS and agonists, antibodies, or antagonists specifically binding HRABS, in the prevention and treatment of diseases associated with expression of HRABS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRABS for the treatment of diseases associated with the expression of HRABS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRABS.Type: GrantFiled: December 27, 1996Date of Patent: February 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, Olga Bandman
-
Patent number: 5869289Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human galectin-8. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human galectin-8. The invention also provides for the production and use of substantially purified human galectin-8 in pharmaceutical compositions to increase immune responses. The invention also provides for the use of antisense molecules and antibodies in pharmaceutical compositions to decrease immune response. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding human galectin-8 and anti-human galectin-8 antibodies which specifically bind to human galectin-8.Type: GrantFiled: October 9, 1996Date of Patent: February 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Olga Bandman
-
Patent number: 5866119Abstract: This invention relates to nucleic acid and amino acid sequences of a new human ribonuclease and to the use of these sequences in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis.Type: GrantFiled: June 2, 1997Date of Patent: February 2, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 5866332Abstract: The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.Type: GrantFiled: February 15, 1996Date of Patent: February 2, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Benjamin Graeme Cocks, Janice Au-Young, Jeffrey J. Seilhamer
-
Patent number: 5863779Abstract: The invention provides a human ubiquitin-conjugating enzyme (HUCE-1) and polynucleotides which identify and encode HUCE-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HUCE-1.Type: GrantFiled: August 21, 1997Date of Patent: January 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley
-
Patent number: 5858675Abstract: The present invention provides a double-stranded RNA-binding protein (BINDR) and polynucleotides which identify and encode BINDR. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of BINDR.Type: GrantFiled: May 13, 1997Date of Patent: January 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
-
Patent number: 5858758Abstract: The present invention provides a human serine protease precursor (HSPP) and polynucleotides which encode HSPP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HSPP.Type: GrantFiled: May 7, 1997Date of Patent: January 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 5856129Abstract: The present invention provides a novel human P.sub.2X purinoreceptor (HPURR) and polynucleotides which identify and encode HPURR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPURR and a method for producing HPURR. The invention also provides for use of HPURR, and agonists, antibodies or antagonists specifically binding HPURR, in the prevention and treatment of diseases associated with expression of HPURR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPURR for the treatment of diseases associated with the expression of HPURR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPURR.Type: GrantFiled: October 30, 1996Date of Patent: January 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Roger Coleman
-
Patent number: 5856128Abstract: The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.Type: GrantFiled: August 15, 1996Date of Patent: January 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
-
Patent number: 5856109Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.Type: GrantFiled: November 7, 1997Date of Patent: January 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott M. Braxton, Dinh Diep, Angelo M. Delegeane
-
Patent number: 5854413Abstract: The present invention provides a polynucleotide (snpg) initially isolated from a colon cDNA library which identifies and encodes a novel human synaptogyrin homolog (SNPG). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SNPG. The invention also provides for the use of SNPG in the membrane of a vesicle containing a chemical or biological therapeutic composition for the treatment of disease, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the abnormal or excess expression of SNPG. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of snpg, or anti-SNPG antibodies which specifically bind to the polypeptide, SNPG.Type: GrantFiled: April 30, 1996Date of Patent: December 29, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Susan G. Stuart, Lynn E. Murry
-
Patent number: 5854046Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.Type: GrantFiled: January 20, 1998Date of Patent: December 29, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman